Oculis Holding AG (OCS) Common Equity (2021 - 2026)

Oculis Holding AG's (OCS) quarterly Common Equity came in at $251.1 million in Q1 2026, up 38.83% year-on-year from $180.9 million in Q1 2025, and up 2.37% quarter-over-quarter from $245.3 million in Q4 2025.

Oculis Holding AG (OCS) Common Equity (2021 - 2026) Analysis & Trends

Oculis Holding AG's Common Equity history runs 6 years deep, the most recent figure standing at $251.1 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 38.83% year-over-year to $251.1 million in Q1 2026; TTM through Mar 2026 was $251.1 million, a 38.83% increase from a year earlier, with the FY2025 full-year figure at $236.5 million, up 183.51% from the prior year.
  • Common Equity grew to $251.1 million in Q1 2026 per OCS's latest filing, from $245.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $251.1 million in Q1 2026 and bottomed at -$101.7 million in Q4 2022.
  • The 5-year median for Common Equity is $124.8 million (2024), against an average of $128.9 million.
  • Across the five-year window, Common Equity sank 53.87% in 2022 and surged 203.88% in 2023, its largest moves.
  • Year by year, Common Equity stood at -$101.7 million in 2022, then jumped by 203.88% to $105.7 million in 2023, then declined by 20.72% to $83.8 million in 2024, then surged by 192.85% to $245.3 million in 2025, then increased by 2.37% to $251.1 million in 2026.
  • Per Business Quant, the three latest OCS Common Equity figures stand at $251.1 million (Q1 2026), $245.3 million (Q4 2025), and $163.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 251.12 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -98.34 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 14.38 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 4.76 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 19.36 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 31.42 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - 795.79 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 1.50 Bn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 1.08 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 251.12 Mn
Dec 31, 2025 245.32 Mn
Sep 30, 2025 163.26 Mn
Jun 30, 2025 172.84 Mn
Mar 31, 2025 180.88 Mn
Dec 31, 2024 83.77 Mn
Sep 30, 2024 109.91 Mn
Jun 30, 2024 124.76 Mn
Mar 31, 2024 90.55 Mn
Dec 31, 2023 105.66 Mn
Sep 30, 2023 119.56 Mn
Jun 30, 2023 130.34 Mn
Dec 31, 2022 -101.72 Mn
Dec 31, 2021 -66.11 Mn